JP2008540336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008540336A5 JP2008540336A5 JP2008509119A JP2008509119A JP2008540336A5 JP 2008540336 A5 JP2008540336 A5 JP 2008540336A5 JP 2008509119 A JP2008509119 A JP 2008509119A JP 2008509119 A JP2008509119 A JP 2008509119A JP 2008540336 A5 JP2008540336 A5 JP 2008540336A5
- Authority
- JP
- Japan
- Prior art keywords
- glp
- agonist
- brs
- composition
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67573005P | 2005-04-27 | 2005-04-27 | |
| US60/675,730 | 2005-04-27 | ||
| PCT/US2006/016024 WO2007027225A2 (en) | 2005-04-27 | 2006-04-26 | Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012090364A Division JP2012136554A (ja) | 2005-04-27 | 2012-04-11 | 肥満および糖尿病、ならびにそれらに関連する病態の処置のため、ならびに血中ｇｌｐ−１レベルを増大させることによって緩和される病態の処置のための、併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008540336A JP2008540336A (ja) | 2008-11-20 |
| JP2008540336A5 true JP2008540336A5 (https=) | 2009-06-18 |
| JP5774264B2 JP5774264B2 (ja) | 2015-09-09 |
Family
ID=37809319
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008509119A Expired - Fee Related JP5774264B2 (ja) | 2005-04-27 | 2006-04-26 | 肥満および糖尿病、ならびにそれらに関連する病態の処置のため、ならびに血中ｇｌｐ−１レベルを増大させることによって緩和される病態の処置のための、併用療法 |
| JP2012090364A Withdrawn JP2012136554A (ja) | 2005-04-27 | 2012-04-11 | 肥満および糖尿病、ならびにそれらに関連する病態の処置のため、ならびに血中ｇｌｐ−１レベルを増大させることによって緩和される病態の処置のための、併用療法 |
| JP2015057165A Pending JP2015120749A (ja) | 2005-04-27 | 2015-03-20 | 肥満および糖尿病、ならびにそれらに関連する病態の処置のため、ならびに血中ｇｌｐ−１レベルを増大させることによって緩和される病態の処置のための、併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012090364A Withdrawn JP2012136554A (ja) | 2005-04-27 | 2012-04-11 | 肥満および糖尿病、ならびにそれらに関連する病態の処置のため、ならびに血中ｇｌｐ−１レベルを増大させることによって緩和される病態の処置のための、併用療法 |
| JP2015057165A Pending JP2015120749A (ja) | 2005-04-27 | 2015-03-20 | 肥満および糖尿病、ならびにそれらに関連する病態の処置のため、ならびに血中ｇｌｐ−１レベルを増大させることによって緩和される病態の処置のための、併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8354241B2 (https=) |
| EP (1) | EP1871362A2 (https=) |
| JP (3) | JP5774264B2 (https=) |
| CN (1) | CN101166527A (https=) |
| AU (1) | AU2006285393A1 (https=) |
| CA (1) | CA2605228A1 (https=) |
| WO (1) | WO2007027225A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| WO2008085888A1 (en) * | 2007-01-05 | 2008-07-17 | Arena Pharmaceuticals, Inc. | G protein-coupled receptor and modulators thereof for the treatment of gaba-related neurological disorders including sleep-related disorders |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| WO2011080276A1 (en) | 2009-12-29 | 2011-07-07 | Genfit | Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative |
| GB201415598D0 (en) * | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
| WO2017151728A1 (en) * | 2016-03-01 | 2017-09-08 | Board Of Supervisors Of Louisiana State Univ. And Agricultural And Mechanical College | Indirect assessment of insulin release in a cell |
| KR20210149366A (ko) * | 2020-06-02 | 2021-12-09 | 주식회사 고바이오랩 | Icam-2에 결합하는 물질을 유효성분으로 포함하는 대사질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5462856A (en) | 1990-07-19 | 1995-10-31 | Bunsen Rush Laboratories, Inc. | Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins |
| US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
| EP1123391A2 (en) | 1998-09-01 | 2001-08-16 | BASF Aktiengesellschaft | Methods for improving the function of heterologous g protein-coupled receptors |
| GB0006289D0 (en) | 2000-03-15 | 2000-05-03 | Smithkline Beecham Plc | New use |
| EP1364024A2 (en) | 2000-11-27 | 2003-11-26 | Arena Pharmaceuticals, Inc. | Endogenous and non-endogenous versions of human g protein-coupled receptors |
| DE10224844A1 (de) | 2002-06-05 | 2004-01-08 | Solvay Pharmaceuticals Gmbh | Nicht-peptidische BRS-3-Agonisten |
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| EP1620555A4 (en) | 2003-04-18 | 2006-09-13 | Merck & Co Inc | BOMBESIN RECEPTOR SUBTYP-3 (BRS-3) FROM RHESUS APPLE, SUCH NUCLEOTIDES AND USES THEREOF |
| PE20050948A1 (es) | 2003-09-09 | 2005-12-16 | Japan Tobacco Inc | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
-
2006
- 2006-04-26 CA CA002605228A patent/CA2605228A1/en not_active Withdrawn
- 2006-04-26 EP EP06824717A patent/EP1871362A2/en not_active Withdrawn
- 2006-04-26 CN CNA2006800142701A patent/CN101166527A/zh not_active Withdrawn
- 2006-04-26 WO PCT/US2006/016024 patent/WO2007027225A2/en not_active Ceased
- 2006-04-26 US US11/919,381 patent/US8354241B2/en not_active Expired - Fee Related
- 2006-04-26 AU AU2006285393A patent/AU2006285393A1/en not_active Withdrawn
- 2006-04-26 JP JP2008509119A patent/JP5774264B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-11 JP JP2012090364A patent/JP2012136554A/ja not_active Withdrawn
- 2012-11-19 US US13/680,866 patent/US9182414B2/en not_active Expired - Fee Related
-
2015
- 2015-03-20 JP JP2015057165A patent/JP2015120749A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2593427A1 (en) | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level | |
| Boer et al. | Incretin hormones and type 2 diabetes—mechanistic insights and therapeutic approaches | |
| Coskun et al. | LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept | |
| Rieg et al. | Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice | |
| JP4562394B2 (ja) | 非アシル化グレリンを含む医薬組成物およびその治療的使用 | |
| JP6185914B2 (ja) | 神経変性疾患の治療に使用するための医薬組成物 | |
| JP2012503013A5 (https=) | ||
| Sass et al. | NK2R control of energy expenditure and feeding to treat metabolic diseases | |
| Ong et al. | Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance | |
| CN101137668A (zh) | 与可溶性G蛋白偶联受体（sGPCR）有关的组合物与方法 | |
| JP2022046619A (ja) | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 | |
| Nelson et al. | Increase in cardiac myosin heavy-chain (MyHC) alpha protein isoform in hibernating ground squirrels, with echocardiographic visualization of ventricular wall hypertrophy and prolonged contraction | |
| JP2008540336A5 (https=) | ||
| CN107847565A (zh) | 用于肌肉减少症治疗的包括胰高血糖素样肽‑1 受体激动剂的药物组合物 | |
| Dalbøge et al. | Neuromedin U inhibits food intake partly by inhibiting gastric emptying | |
| CN114621327B (zh) | GLP-1、GIP和Gcg多重受体激动蛋白质 | |
| WO2007134613A1 (en) | Modulation of gpr120 activity in adipocytes/fat tissue | |
| CN116333043A (zh) | 具有抗肥胖及抗糖尿病功效的肽及其用途 | |
| Nakao | Translational science: Newly emerging science in biology and medicine—Lessons from translational research on the natriuretic peptide family and leptin— | |
| Matlik et al. | Clinical and molecular analysis of a novel COLQ missense mutation causing congenital myasthenic syndrome in a Syrian family | |
| Jeromson et al. | Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet‐induced obesity | |
| Li | Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer’s disease? | |
| US20120157379A1 (en) | Gastric Inhibitory Peptide Variants and Their Uses | |
| CN118221798B (zh) | 一种新型的glp-1r肽类激动剂及其应用 | |
| Gupta et al. | Association of Circulating Orexin-A Level with Metabolic Risk Factors in North Indian Pre-Menopausal Women |